Beinaglutide shows significantly beneficial effects in diabetes/obesity-induced nonalcoholic steatohepatitis in ob/ob mouse model.

Abstract

AIMS:

Beinaglutide has been approved for glucose lowering in type 2 diabetes mellitus (T2DM) in China. In addition to glycemic control, significant weight loss is observed from real world data. This study is designed to investigate the pharmacological and pharmacokinetic profiles of beinaglutide in different models.

METHODS:

The pharmacological efficacy of beinaglutide was evaluated in C57BL/6 and ob/ob mice after single administration. Pharmacokinetic profiles in mice were investigated after single or multiple administration. Sub-chronic pharmacological efficacy was investigated in ob/ob mice for two weeks treatment and diet-induced ob/ob mice model of nonalcoholic steatohepatitis (NASH) for four weeks treatment.

KEY FINDINGS:

Beinaglutide could dose-dependently reduce the glucose levels and improve insulin secretion in glucose tolerance tests, inhibit food intake and gastric emptying after single administration. At higher doses, beinaglutide could inhibit food intake over 4 h, which results in weight loss in ob/ob mice after about two weeks treatment. No tachyphylaxis is observed for beinaglutide in food intake with repeated administration. In NASH model, beinaglutide could reduce liver weight and hepatic steatosis and improve insulin sensitivity. Signiant changes of gene levels were observed in fatty acid β-oxidation (Ppara, Acadl, Acox1), mitochondrial function (Mfn1, Mfn2), antioxidation (Sod2), Sirt1, and et al. SIGNIFICANCE: Our results characterize the pharmacological and pharmacokinetic profiles of beinaglutide in mice and supported that chronic use of beinaglutde could lead to weight loss and reduce hepatic steatosis, which suggest beinaglutide may be effective therapy for the treatment of obesity and NASH.

• Authors: Xiankang Fang, Zhiqiang Du, Chunling Duan, Shanshan Zhan, Tian Wang, Mengyu Zhu, Jiajie Shi, Juan Meng, Xianhua Zhang, Maiyun Yang, Yajun Zuo
• Journal: Life sciences (Life Sci) Vol. 270 Pg. 118966 (Apr 01 2021) ISSN: 1879-0631 [Electronic] Netherlands
• PMID: 33482185 (Publication Type: Journal Article)
• Copyright: Copyright © 2021 Elsevier Inc. All rights reserved.

Chemical References

• Antioxidants
• Hypoglycemic Agents
• Insulin
• Leptin
• PPAR alpha
• Peptide Fragments
• Liraglutide
• Glucagon-Like Peptide 1

Topics

• Animals
• Antioxidants (pharmacology)
• Diabetes Complications (drug therapy)
• Diabetes Mellitus (drug therapy, metabolism)
• Glucagon-Like Peptide 1 (analogs & derivatives, metabolism, pharmacology)
• Hypoglycemic Agents (metabolism, pharmacology)
• Insulin (metabolism)
• Insulin Resistance
• Leptin (metabolism)
• Liraglutide (pharmacology)
• Liver Cirrhosis (metabolism, pathology)
• Male
• Mice
• Mice, Inbred C57BL
• Mice, Obese
• Non-alcoholic Fatty Liver Disease (drug therapy, metabolism)
• Obesity (complications, metabolism)
• Oxidation-Reduction
• PPAR alpha (metabolism)
• Peptide Fragments (chemistry, pharmacology)
• Weight Loss (drug effects)